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Background: Primary melanoma of the prostate has an extremely rare incidence. Only five cases have been
reported in the literature and prognosis is poor. The most likely origin of prostatic melanoma is the transitional
epithelium of the prostatic urethra. Surgical care for primary melanoma of mucosal sites is less well established
than for primary cutaneous melanoma, but excision of the primary is recommended if the patient has no systemic
disease.
Case presentation: Here, we describe a case of primary malignant melanoma of the prostate. A 37-year-old male
patient with history of both chemo- and radiation therapy for Hodgkin’s disease was admitted to the University
Hospital Heidelberg on suspicion of pleomorphic sarcoma of the bladder. In-house diagnostic work-up revealed a
malignant melanoma of the prostate. We then performed radical prostatectomy with extended lymphadenectomy.
Despite presumably curative surgery, the patient suffered from early relapse of disease with pulmonary metastasis.
Systemic chemotherapy and subsequent immuno-oncologic treatment was thereafter initiated.
Conclusion: Since prostatic melanoma is a rare disease and a melanoma metastasis of unknown primary is the
differential diagnosis, a multidisciplinary approach including early imaging to rule out possible metastases and
to search for another potentially existing primary is advisable. To prevent complications related to local tumor
progression and to receive tissue for mutational analysis, we recommend complete surgical resection to reduce
the tumor mass. Novel immune and targeted oncologic therapies can lead to an improved survival in some cases
and support of clinical trials is needed.
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Primary melanoma of the prostate has an extremely rare
incidence. The first report of this disease was in 1980.
Since then only five cases have been reported world-
wide [1–5]. We report on one case including diagnosis,
surgical management, and subsequent therapy with dar-
cabazine, ipilimumab and nivolumab.
Case presentation
A 37-year old man was admitted to the University
Hospital Heidelberg for a second opinion after diagnosis
of a pleomorphic sarcoma of the bladder in April 2012.
His medical history included Hodgkin’s disease stage IIb* Correspondence: georgi.tosev@med.uni-heidelberg.de
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cular and mediastinal lymph nodes. In 2004 he received
two cycles each of BEACOPP and ABVD chemotherapy,
resulting in complete remission. Consolidating treatment
consisted of involved-field radiotherapy with 30 Gy in
2005.
The patient reported that one month before his first
consultation at our Clinic he suffered from macrohae-
maturia and urinary retention. He was admitted to an
outside urology unit and a transurethral resection was
performed. Histopathology reported a pleomorphic sar-
coma of the bladder neck with malignant melanoma as a
possible differential diagnosis.
Neither digital rectal examination, nor a serum prostate
antigen of 1.57 ng/ml, were indicative of primary prostate
cancer, but in-house cystoscopy showed an asymmetric
prostate enlargement with purple discoloration. Thus,icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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results, followed by a diagnostic TUR-P yielding two speci-
mens from the dubious area of the left prostate lobe above
the level of the verumontanum. Final histopathology and
immunohistochemical staining showed positive expression
of Vimentin, Melan A, CD56, and HMB 45 and negative
expression of CD30, Desmin, PSMA, S100, AE 1/3, CD34,
LCA, PLAP, BerEp4, EMA, CD68, Inhibin and Calretinin,
which confirmed the diagnosis of a melanoma [6]. Clear
cell sarcoma was excluded via the lack of EWSR-ATF-1
translocation in the areas of the lesion analyzed.
No evidence for primary melanoma at other sites, par-
ticulary skin and mucosal by dermatologic, ophthalmo-
logic and otolaryngologic examinations, as well as
colonoscopy and gastroscopy, or distant metastases were
found on imaging (CT with contrast of chest and
abdomen and pelvic MRI with contrast in April 2012;
Fig. 1, Ia and Ib). Therefore, open retropubic radical
prostatectomy with extended lymph-node dissection was
performed with curative intention in June 2012. Histo-
pathologic examination (Fig.1, IIa, IIb, IIc) revealed a
primary melanoma of the prostate with clear surgical
margins (pR0) and tumour-free lymph nodes (pN0 0/
22). One year after surgery the patient was completely
continent and reported normal erectile function. Add-
itionally, follow-up imaging did not show any local
recurrence in the small pelvis. However CT imaging of
the chest and, abdomen, and an MRI of the head with
contrast in October 2012 and January 2013 (Fig. 1, IIIa)
detected multiple small pulmonary lesions of up to 24
mm in size, suspicious for pulmonary metastases. Bron-
choscopy was performed and biopsies from the pulmon-
ary nodules were taken. Histopathology showed
metastases of the melanoma confirming systemic re-
lapse. According to the results of subsequent molecular
analyses, no BRAF, cKIT, NRAS or GNAQ mutations
and again no EWSR-1-translocation were identified. Sys-
temic therapy with DTIC (Dacarbazine) 1000mg/m2 for
three cycles was initiated. Due to disease progression
(Fig. 1, IIIb), therapy was switched to Ipilimumab (3 mg/
kg). Staging after four cycles of Ipilimumab again re-
vealed a massive disease progression and the patient was
subsequently included in a phase three study of an anti-
PD1 antibody receiving five cycles (NCT 01721746). As
before, the patient experienced a pronounced progres-
sion of lung and hilar lymph node metastases (Fig. 1,
IIIc). Another treatment regimen consisting of chemo-
therapy with carboplatin and paclitaxel was offered to
the patient, but was declined. The patient died 16
months after initial diagnosis in palliative care.
Consent
Written informed consent was obtained from the par-
ents of the patient for publication of this Case reportand any accompanying images. A copy of the written
consent is available for review by the Editor of this
journal.
Discussion
Primary melanoma of the prostate is exceedingly rare. In
the present case our patient suffered from melanoma of
the prostate as a secondary malignancy.
The patient’s history of Hodgkin disease (HD) and
prior treatment with chemotherapy and radiochemother-
apy (RT) may play a pathogenetic role in the develop-
ment of the secondary malignancy. HD often involves
cervical and mediastinal lymph nodes, and RT is known
to target these nodal regions resulting in the irradiation
of adjacent mammary tissue and lung. The risk of
secondary lung cancer, breast, bladder, gastric and
oesophageal cancer has been associated with radiation
dose and with field size, but it is mostly described > 10
years after treatment [7, 8]. Similarly, secondary malig-
nancy rates after BEACOPP-chemotherapy are 5.7–6 %,
respectively [9]. Among adult survivors of childhood
cancer, the prevalence of adverse health outcomes is
high and an ongoing health monitoring for this group of
patients is very important [10]. Due to the uncommon
localization, no previous staging CT or MRI included
the prostate in the present case. Only symptoms of lo-
cally advanced disease such as hematuria and urinary re-
tention lead to further diagnostic work-up and to the
final diagnosis. As seen on upon MRI analysis, the loca-
tion of the tumor was in the transition zone of the pros-
tate. Thus, the most likely origin of the prostatic
melanoma was the transitional epithelium of the pros-
tatic urethra. However, we cannot completely exclude
that the patient had a stage IV melanoma with unknown
primary where the prostate was the first location of me-
tastases. In disseminated metastatic melanoma it has
been reported that the prostate may be involved in 3 %
of autopsies.
Initial management of cutaneous melanoma after bi-
opsy is directed by depth of tumor, presence of ulcer-
ation, and dermal mitoses and may involve wide local
excision with margins ranging from 1 to 2 cm plus/
minus sentinel lymph node biopsy, and adjuvant inter-
feron or immuno-oncologic therapy depending on final
staging [11]. Surgical care for primary melanoma of mu-
cosal sites is less well established than for primary cuta-
neous melanoma, but excision of the primary is always
the goal if the patient has no systemic disease.
Despite low chances of a cure, we performed radical
prostatectomy (RP) with extended lymph node dissec-
tion due to clinical lower urinary tract symptoms and to
prevent further local complications. RP is a strong inde-
pendent predictor of survival benefit in patients with
prostate cancer [12]. However, radical prostatectomy can
Fig. 1 Case time-line
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low volume hospitals [13]. Thus, the decision of dissection
of the tumor was an individual approach, based on
the current knowledge of the treatment of prostate
carcinoma and melanoma and based on the fact that
macrohaematuria and lower urinary tract symptomssignificantly impair quality of life. In the present case,
the patient fully recovered lower urinary tract function
after surgery.
Unfortunately, the patient suffered from systemic re-
lapse with pulmonary metastases shortly afterwards.
Systemic therapy was initiated, and 16 months after
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ure. Advanced imaging such as PET/CT may have de-
tected systemic disease earlier than the staging we had
performed. However, first metastases occurred in the
lungs for which PET scanning is not clearly superior to
CT. In addition, the management of the patient would
not have changed significantly since one of the main in-
dications for surgery was to improve micturition and to
prevent local complications.
Systemic therapeutic options for advanced melanoma
have substantially increased over the last several years.
They can be divided into targeted therapies such as
BRAF, MEK, cKIT inhibitors or immuno-oncologic
treatments such as CTLA4 and PD-(L)-1 antibodies
which manipulate the immune system. At present, trials
are addressing various combination therapies to improve
overall survival.
Melanomas arising in visceral organs are less likely to
be BRAF or NRAS positive. While mucosal melanomas
are more likely to have cKIT mutations and if positive
can benefit from targeted therapy such as tyrosine kinase
inhibition, this was not the case in our patient. In the
case report of Ma et al. before novel immunotherapeutic
drugs were available, the patient survived three months
on systemic treatment. Although our patient showed
disease progression under therapy with novel immuno-
therapeutics, the overall survival was better than the
case stated above. Whether this means that tumor
growth was slowed down under treatment with check-
point inhibitors is at this point speculative.
Interestingly, the anti-cytotoxic T lymphocyte-associated
receptor 4 (CTLA4) antibody Ipilimumab is also under in-
vestigation for patients with metastatic, castration-resistant
prostate cancer (mCRPC) [14].
Conclusion
Due to the extreme rarity of prostatic melanoma, only
very few cases have been reported. This increases the
scientific importance of each individual case report. A
multidisciplinary team approach to search for another
potentially existing primary and early imaging to rule
out possible metastases are advisable. In case of prostatic
melanoma we recommend complete surgical resection
with extended lymphadenectomy by experienced sur-
geons to prevent complications related to local tumor
progression.
Advanced melanoma shows a wide heterogeneity and
testing for different mutations of the tumor is needed to
choose drug regimens individually for the patient. Novel
immuno-oncologic therapy may lead to an improved
survival in some cases.
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